VC-backed Raze Therapeutics names new VP

Raze Therapeutics has hired Dr. Mikel Moyer as vice president of molecular discovery. The appointment becomes effective November 1. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs. Its backers include Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis.


Bicycle Therapeutics reels in $32 mln

Bicycle Therapeutics has raised $32 million in funding. Previous backers Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management all participated in the round. Based in Cambridge, UK, Bicycle Therapeutics is a biotech firm focused on developing bicyclic peptides.

Raze Therapeutics attracts $24 mln Series A

Raze Therapeutics has raised $24 million in Series A financing. The investors include Atlas Venture, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis. In addition to the funding, Jason Rhodes, an Atlas partner, has joined the board and is serving as acting CEO. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Epizyme Files for an IPO

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

Fate Therapeutics Appoints chairman and interim CEO

San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock. Fate Therapeutics has secured venture backing from OVP Venture Partners, Astellas Venture Management, Genzyme Ventures, ARCH Venture Partners, Polaris Venture Partners and Venrock. PRESS RELEASE Fate Therapeutics, Inc. […]

Cleave Biosciences Raises $42M Series A

Cleave Biosciences has raised $42 million in venture capital to develop new treatments for cancer. The Series A round investors include U.S. Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management. The financing will support multiple small molecule discovery and development programs in the area of protein homeostasis, the company said.

Verastem Nabs $32M in Series B

Boston-based Verastem has raised $32 million in Series B financing, only eight months after wrapping up a $16 million Series A round. Advanced Technology Ventures and Astellas Venture Management led the Series B, and were joined by all previous investors: Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. The money will support ongoing research and development. Verastem is and developing drugs to treat breast and other cancers by targeting cancer stem cells.

PhaseBio Pharma Adds $15M in Series B Financing

PhaseBio Pharmaceuticals has closed a $25 million Series B round after adding $15 million in venture capital and nearly $500,000 in grants. The company, based in Malvern, Penn., is developing drugs to treat diabetes, metabolic disease and cardiovascular disease. Investors include Astellas Venture Management, Johnson & Johnson Development Corporation, Hatteras Venture Partners and Fletcher Spaght Ventures.

DecImmune gets $3.2M funding

DecImmune Therapeutics, a Massachusetts-based medical research company, received a $1 million equity investment from Astellas Venture Management, the company has announced. DecImmune also received $2.2 million in Phase II Small Business Innovation Research funding from the National Institutes of Health. Amgen Ventures and HealthCare Ventures also participated in the financing.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget